The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Gottesman, Michael M ^a   Pastan, Ira H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

CANCER RESISTANCE; GENE EXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; NEOPLASMS; PUBLICATION; RESEARCH; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; P-GLYCOPROTEINS; PERIODICALS AS TOPIC; RESEARCH DESIGN; RESEARCH REPORT; UNITED STATES;

EID: 84942251546     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv222     Document Type: Note

References (27)

1. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989;81(2):116-124.
2. Gillet JP, Calcagno AM, Varma S, et al. Redefning the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 2011;108(46):18708-18713.
3. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452-458.
4. Szakács G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profling ABC transporter genes in cancer cells. Cancer Cell. 2004;6(2):129-137.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
6. Keniya MV, Holmes AR, Niimi M, et al. Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. Mol Pharm. 2014;11(10):3452-3462.
7. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258(5088):1650-1654.
8. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95(26):15665-15670.
9. Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985;45(7):3002-3007.
10. Kakehi Y, Kanamaru H, Yoshida O, et al. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol. 1988;139(4):862-865.
11. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst. 1989;81(11):844-849.
12. Lai SL, Goldstein LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989;81(15):1144-1150.
13. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Bénard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 1989;49(18):5062-5065.
14. Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res. 1990;14(1):11-21.
15. Gillet JP, Calcagno AM, Varma S, et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res. 2012;18(11):3197-3206.
16. Gillet JP, Wang J, Calcagno AM, et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011;8(6):2080-2088.
17. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489-494.
18. Huff LM, Lee JS, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem. 2006;281(48):36501-36509.
19. Basseville A, Hall M, Chau CH, et al. The ABCG2 multidrug transporter. In: Anthony G, ed. ABC Transporters-40 Years On. New York, NY: Springer; In press.
20. Patel C, Stenke L, Varma S, et al. Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer. 2013;119(16):3076-3083.
21. Pajic M, Iyer JK, Kersbergen A, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 2009;69(16):6396-6404.
22. Rottenberg S, Borst P. Drug resistance in the mouse cancer clinic. Drug Resist Updat. 2012;15(1-2):81-89.
23. Ozols RF, Cunnion RE, Klecker RW Jr, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987;5(4):641-647.
24. Shaffer BC, Gillet J P, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1-2):62-69.
25. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug effux pump inhibitor. Expert Rev Anticancer Ther. 2007;7(4):447-459.
26. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-gly-coprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116(20):4077-4085.
27. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012;15(1-2):98-105.